

Memo

CEC Ref: D21/12022

TO:	Chief Executives, Local Health Districts/ Specialty Health Networks		
FROM:	Ms Carrie Marr, Chief Executive		
TEL:	DATE:	12 May 2021	
SUBJECT:	Enoxaparin (Clexane®) 20 mg and 40 mg syringes – Disruption to supply		


There is a national disruption to the supply of enoxaparin (Clexane®) 20 mg and 40 mg syringes due to manufacturing delays. Supply of these products is expected to return in early June 2021.

To supplement the very limited supply available at wholesalers, access to the NSW HealthShare stock is open for both strengths. Pharmacy Departments should follow the process distributed by HealthShare NSW to order stock via iProcurement. LHD/SHN approvers are requested to approve these orders as a matter of priority to facilitate timely access to this important medication. Each order will be evaluated based on historical usage to ensure equitable stock allocation, with priority given to those most in need.

We ask that you communicate this information to General Managers, Directors of Medical Services, Directors of Allied Health (where relevant), Directors of Pharmacy, Drug and Therapeutics Committees, and other relevant staff and committees.

For urgent stock requirements, or if problems are encountered when submitting a request, please contact Noman Masood – Senior Category Manager, Strategic Procurement Services (HealthShare NSW) on 8797 6890 or email Noman.Masood@health.nsw.gov.au

Yours sincerely



Ms Carrie Marr
CHIEF EXECUTIVE



CLINICAL
EXCELLENCE
COMMISSION

Locked Bag 2030
St Leonards NSW 1590
p. +61 2 9269 5500
www.cec.health.nsw.gov.au